HRT Financial LP Grows Holdings in Xencor, Inc. (NASDAQ:XNCR)

Posted by Defense World Staff on Jun 3rd, 2023

HRT Financial LP increased its position in Xencor, Inc. (NASDAQ:XNCR – Get Rating) by 21.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,366 shares of the biopharmaceutical company’s stock after acquiring an additional 4,804 shares during the quarter. HRT Financial LP’s holdings in Xencor were worth $712,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in XNCR. Primecap Management Co. CA increased its holdings in Xencor by 18.7% in the 3rd quarter. Primecap Management Co. CA now owns 5,690,231 shares of the biopharmaceutical company’s stock worth $147,832,000 after acquiring an additional 895,179 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Xencor by 12.7% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 6,599,071 shares of the biopharmaceutical company’s stock worth $180,617,000 after acquiring an additional 744,569 shares in the last quarter. State Street Corp increased its holdings in Xencor by 19.7% in the 1st quarter. State Street Corp now owns 2,968,901 shares of the biopharmaceutical company’s stock worth $79,210,000 after acquiring an additional 488,131 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Xencor by 348.6% in the 2nd quarter. Goldman Sachs Group Inc. now owns 521,781 shares of the biopharmaceutical company’s stock worth $14,281,000 after acquiring an additional 405,458 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in Xencor in the 1st quarter worth approximately $6,267,000. 98.99% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Canaccord Genuity Group dropped their price target on Xencor from $48.00 to $42.00 and set a “buy” rating for the company in a research note on Friday, February 24th. StockNews.com assumed coverage on Xencor in a research note on Thursday, May 18th. They issued a “sell” rating for the company. Mizuho restated a “buy” rating and issued a $59.00 price target on shares of Xencor in a research note on Friday, February 10th. SVB Leerink reiterated an “outperform” rating on shares of Xencor in a research report on Thursday, February 23rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Xencor in a research report on Monday, May 15th. One investment analyst has rated the stock with a sell rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Xencor currently has an average rating of “Moderate Buy” and a consensus target price of $45.33.

Xencor Stock Performance

Shares of XNCR opened at $27.69 on Friday. The business has a fifty day moving average of $27.70 and a 200 day moving average of $29.18. Xencor, Inc. has a 52-week low of $19.35 and a 52-week high of $38.20.

Xencor (NASDAQ:XNCR – Get Rating) last issued its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($1.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.27). The company had revenue of $18.90 million during the quarter, compared to the consensus estimate of $26.89 million. Xencor had a negative return on equity of 19.41% and a negative net margin of 142.32%. The firm’s quarterly revenue was down 77.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.39 earnings per share. As a group, equities research analysts forecast that Xencor, Inc. will post -2.99 EPS for the current fiscal year.

Insiders Place Their Bets

In other Xencor news, CEO Bassil I. Dahiyat sold 2,602 shares of the stock in a transaction on Thursday, March 9th. The stock was sold at an average price of $29.88, for a total value of $77,747.76. Following the sale, the chief executive officer now owns 249,701 shares in the company, valued at $7,461,065.88. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Xencor news, CEO Bassil I. Dahiyat sold 2,602 shares of the stock in a transaction on Thursday, March 9th. The stock was sold at an average price of $29.88, for a total value of $77,747.76. Following the sale, the chief executive officer now owns 249,701 shares in the company, valued at $7,461,065.88. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Celia Eckert sold 2,462 shares of the stock in a transaction on Monday, March 6th. The stock was sold at an average price of $31.42, for a total value of $77,356.04. Following the completion of the sale, the vice president now owns 37,687 shares in the company, valued at approximately $1,184,125.54. The disclosure for this sale can be found here. Insiders have sold a total of 19,543 shares of company stock worth $607,254 over the last quarter. Company insiders own 4.97% of the company’s stock.

About Xencor

(Get Rating)

Xencor, Inc is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions.

HRT Financial LP Grows Holdings in Xencor, Inc. (NASDAQ:XNCR)

Wall Street Analyst Weigh In

Xencor Stock Performance

Insiders Place Their Bets

About Xencor

See Also

You might be interested in: